Advanced Practice Provider Perspectives on the Long-Term Safety of Oral Plaque Psoriasis Therapies - Episode 7
Safety Data on Deucravacitinib
Advances practice providers in dermatology discuss the safety data on the novel TYK2 inhibitor deucravacitnib.
Summary
In this series, dermatologists TJ Chao and Kristine Kucera delve into recent developments in plaque psoriasis treatment, including the emergence of TYK2 inhibitors. They highlight the evolving role of physician assistants in managing plaque psoriasis and discuss its recognition as a systemic disease. The conversation covers lab and monitoring requirements for TYK2 inhibitors like deucravacitinib, alongside a review of short- and long-term clinical trial data. Chao and Kucera offer insights into patient selection and the patient experience with oral systemic agents, providing guidance for selecting appropriate therapies in the expanding treatment landscape.
This summary was AI-generated and edited for clarity.
